Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2025

Publication ID:

PB504250858

Publication Date:

April 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Active Pharmaceutical Ingredients (API) CDMO was valued at US$ 62590 million in the year 2024 and is projected to reach a revised size of US$ 107850 million by 2031, growing at a CAGR of 8.2% during the forecast period.
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.
This report aims to provide a comprehensive presentation of the global market for Active Pharmaceutical Ingredients (API) CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Active Pharmaceutical Ingredients (API) CDMO.
The Active Pharmaceutical Ingredients (API) CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Active Pharmaceutical Ingredients (API) CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Active Pharmaceutical Ingredients (API) CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Segment by Type
Macromolecular API
Small Molecule API
Segment by Application
Clinical
Commercial
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Active Pharmaceutical Ingredients (API) CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Macromolecular API
1.2.3 Small Molecule API
1.3 Market by Application
1.3.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Clinical
1.3.3 Commercial
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Perspective (2020-2031)
2.2 Global Active Pharmaceutical Ingredients (API) CDMO Growth Trends by Region
2.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Region (2020-2025)
2.2.3 Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Region (2026-2031)
2.3 Active Pharmaceutical Ingredients (API) CDMO Market Dynamics
2.3.1 Active Pharmaceutical Ingredients (API) CDMO Industry Trends
2.3.2 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
2.3.3 Active Pharmaceutical Ingredients (API) CDMO Market Challenges
2.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue
3.1.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue (2020-2025)
3.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Active Pharmaceutical Ingredients (API) CDMO Revenue
3.4 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio
3.4.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2024
3.5 Global Key Players of Active Pharmaceutical Ingredients (API) CDMO Head office and Area Served
3.6 Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Product and Application
3.7 Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Type
4.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Type (2020-2025)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Type (2026-2031)
5 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Application
5.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Application (2020-2025)
5.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
6.2 North America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
6.4 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
7.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
9.2 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
9.4 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm
11.1.1 Recipharm Company Details
11.1.2 Recipharm Business Overview
11.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Introduction
11.1.4 Recipharm Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.1.5 Recipharm Recent Development
11.2 Cambrex Corporation
11.2.1 Cambrex Corporation Company Details
11.2.2 Cambrex Corporation Business Overview
11.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Introduction
11.2.4 Cambrex Corporation Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.2.5 Cambrex Corporation Recent Development
11.3 Patheon (Thermo Fisher Scientific)
11.3.1 Patheon (Thermo Fisher Scientific) Company Details
11.3.2 Patheon (Thermo Fisher Scientific) Business Overview
11.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Introduction
11.3.4 Patheon (Thermo Fisher Scientific) Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.3.5 Patheon (Thermo Fisher Scientific) Recent Development
11.4 CordenPharma
11.4.1 CordenPharma Company Details
11.4.2 CordenPharma Business Overview
11.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Introduction
11.4.4 CordenPharma Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.4.5 CordenPharma Recent Development
11.5 Lonza
11.5.1 Lonza Company Details
11.5.2 Lonza Business Overview
11.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Introduction
11.5.4 Lonza Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.5.5 Lonza Recent Development
11.6 Siegfried
11.6.1 Siegfried Company Details
11.6.2 Siegfried Business Overview
11.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Introduction
11.6.4 Siegfried Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.6.5 Siegfried Recent Development
11.7 Catalent
11.7.1 Catalent Company Details
11.7.2 Catalent Business Overview
11.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Introduction
11.7.4 Catalent Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.7.5 Catalent Recent Development
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Details
11.8.2 Boehringer Ingelheim Business Overview
11.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Introduction
11.8.4 Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.8.5 Boehringer Ingelheim Recent Development
11.9 Piramal Group
11.9.1 Piramal Group Company Details
11.9.2 Piramal Group Business Overview
11.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.9.4 Piramal Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.9.5 Piramal Group Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Details
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Introduction
11.10.4 AbbVie Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.10.5 AbbVie Recent Development
11.11 SGS Quay Pharmaceuticals
11.11.1 SGS Quay Pharmaceuticals Company Details
11.11.2 SGS Quay Pharmaceuticals Business Overview
11.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Introduction
11.11.4 SGS Quay Pharmaceuticals Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.11.5 SGS Quay Pharmaceuticals Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Details
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.12.4 Aenova Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.12.5 Aenova Group Recent Development
11.13 Curia
11.13.1 Curia Company Details
11.13.2 Curia Business Overview
11.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Introduction
11.13.4 Curia Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.13.5 Curia Recent Development
11.14 Sterling Pharma Solutions
11.14.1 Sterling Pharma Solutions Company Details
11.14.2 Sterling Pharma Solutions Business Overview
11.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Introduction
11.14.4 Sterling Pharma Solutions Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.14.5 Sterling Pharma Solutions Recent Development
11.15 Eurofins CDMO
11.15.1 Eurofins CDMO Company Details
11.15.2 Eurofins CDMO Business Overview
11.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Introduction
11.15.4 Eurofins CDMO Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.15.5 Eurofins CDMO Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂